Abbott IVD manufacturing facility reinspection by FDA expected in next few weeks.
This article was originally published in The Gray Sheet
Executive Summary
ABBOTT REINSPECTION BY FDA TO ADDRESS IVD MANUFACTURING DEFICIENCIES is expected to take place in the next few weeks, according to the firm. The reinspection of the company's Abbott Park, Illinois in vitro diagnostic production facilities is intended to verify that Abbott has completed corrective actions taken in response to violations of good manufacturing practices found by FDA during audits in 1993 and 1994. The upcoming inspection will be conducted jointly by FDA's Chicago District Office and centers for devices and biologics.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.